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Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of 
lymphoid proliferations that occur in the setting of depressed T-cell function due to 
immunosuppressive therapy used following solid organ transplantation, 
hematopoietic stem cell transplantation and also xenotransplantation. In the present 
study, 28 immunosuppressed parkinsonian Macaca fascicularis were intracerebrally 
injected with wild-type or CTLA4-Ig transgenic porcine xenografts to identify a 
suitable strategy to enable long-term cell survival, maturation and differentiation. 
Nine of 28 (32%) immunosuppressed primates developed masses compatible with 
PTLD, located mainly in the gastrointestinal tract and/or nasal cavity. The masses 
were classified as monomorphic PTLD according to the WHO classification. 
Immunohistochemistry and PCR analyses revealed that the PTLDs were associated 
with macaca lymphocryptovirus as confirmed by double-labeling 
immunohistochemistry for CD20 and EBNA2, where the viral protein was located 
within the CD20-positive neoplastic B cells. In sera from three distinct phases of the 
experimental life of the primates, testing by quantitative PCR revealed a progression 
of the viral load that paralleled the PTLD progression, and no evidence of zoonotic 
transmission of porcine lymphotropic herpesvirus through xenoneuronal grafts. 
These data suggest that monitoring the variation of macaca lymphocryptovirus DNA 
in primates could be used as a possible early diagnostic tool for PTLD progression 
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Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of 
lymphoproliferative diseases that arise after transplantation of solid organ and other 
tissues.9 They comprise a wide spectrum of clinical and pathological manifestations 
ranging from a benign self-limited form of lymphoproliferation to an aggressive and 
disseminated lymphoma.2 PTLD incidence is as high as 10% in solid organ 
transplantation 4 and may occur at any time after transplantation, but the risk 
appears to be greatest within the first year post transplantation.19 PTLD WHO 
classification recognizes three main pathologic subsets of the lymphoproliferative 
lesions: early, polymorphic, and monomorphic lesions. 21 Early lesions, more 
frequently involving tonsils, adenoids or lymph nodes than extranodal sites, include 
two morphological types: plasma cell hyperplasia and infectious mononucleosis-like 
lesions. Polymorphic PTLDs affect nodal and extranodal tissues and show loss of 
tissue architecture and necrosis. Polymorphic PTLDs are composed of a mixed 
population of immunoblasts, plasma cells, intermediate-sized lymphoid cells 
(incorporating a full range of B-cell morphology and differentiation), as well as 
occasional Hodgkin Reed Sternberg-like cells. Monomorphic PTLDs can be either of 
B cell or T-cell lineage, disturb the tissue architecture and spread to other organs. 
They are classified according to the WHO classification of lymphomas in 
immunocompetent patients, showing features of different morphologic variants of 
diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), or plasmablastic 
lymphoma (PL).21  
Approximately 50-80% of PTLD biopsies are positive for human herpesvirus 4 or 
Epstein Barr virus (EBV) within the tumor cells, reflecting the critical role of reduced 




EBV-related herpesvirus, or lymphocryptovirus (LCV) is similarly associated with 
lymphomas in immunosuppressed non-human primates (NHP).22 In common with 
human EBV infection, primate LCV is endemic in Old World macaques, both those 
born in the wild and those raised in captivity, and resides latently in B cells in most 
adult animals.16 Likewise, porcine lymphotropic herpesviruses (PLHV) are 
widespread among domestic pig populations5 and have been associated with PTLD 
in pigs receiving allogeneic hematopoietic cell transplants.11 Although the zoonotic 
potential of PLHVs is unknown, PLHV-related PTLD should be considered a risk in 
recipients of porcine derived xenografts. This small risk should be diminished by the 
use of specific pathogen free housed donor animals.10 
Several reports have suggested that the use of cyclosporine in NHP, either alone or 
in combination with conventional immunosuppressive therapy, might be associated 
with an increased risk of lymphoma.16 Malignant lymphomas were detected in two of 
five non-transplanted cynomolgus monkeys receiving cyclosporine and in simian 
immunodeficiency virus (SIV)-immunosuppressed cynomolgus and rhesus 
monkeys.13 These lymphomas were mostly extranodal, aggressive and in all cases 
associated with LCV.16 Endogenous LCV is capable of producing PTLD in 
immunosuppressed macaques that are recipients of kidney allografts with a 
frequency of 9 of 160 (5.6%).20 Similarly, in a kidney xenotransplantation from pig to 
cynomolgus monkey and in kidney allotransplantation, LCV-related PTLD developed 
in 10 of 245 xenotransplanted (pig to cynomolgus monkey) (4%) and 9 of 231 (3,8%) 
allotransplanted primates.16 The prevalence of PTLD is probably determined by the 
intensity of immunosuppression and not by the regimen used. The highest frequency 
of PTLD occurred in those animals that were on an aggressive immunosuppressive 




use of a particular drug or drug combination in maintenance of immunosuppression 
and the occurrence of PTLD.16 Furthermore, a high dose regimen of 
cyclophosphamide and rapamycin led to a high incidence of PTLD in a life-
supporting functional kidney and liver baboon-to-monkey grafts.23 In a non-human 
primate model of facial composite tissue allotransplantation, a continuous infusion of 
tacrolimus provided prolonged rejection-free survival of the grafts. This was 
associated with a high frequency of donor-derived PTLD, possibly due to a large 
volume of transplanted vascularized bone marrow.3 In summary, in humans the 
pathogenesis of PTLDs seems to be multifactorial: aside from the accumulation of 
genetic alterations of oncogenes and tumor suppressor genes, the role of EBV, 
among the possible infective causes, seems to be central in driving the proliferation 
of EBV-infected B cells and subsequent development of the lymphoproliferative 
disorder in the setting of a prolonged and profound immunosuppression which 
decreases the pool of specific cytotoxic T lymphocytes.7-21 
In this study we characterize PTLD occurring in the setting of neural precursors 
xenotransplantation to treat a pharmacologically-induced form of Parkinson’s 
disease (PD),1 with respect to tissue localization, histopathology, immunophenotype 









Materials and Methods 
Animals 
Twenty-eight, purpose-bred, 6- to 12-year-old, 20 females and 8 males, cynomolgus 
monkeys (Macaca fascicularis) from a breeding center in the Philippines, weighing 
between 2.7 and 6.5 kg, were included in this study. The primates were screened for 
zoonotic and simian diseases before joining the trial. Complete hematological and 
biochemical screening, fecal analysis for intestinal worms and protozoa, tuberculosis 
test and viral serology were also performed. All experiments and procedures were 
conducted in accordance with the Italian law (Law no. 116 of the 27/01/1992) and 
with the decree of the Ministry of Health 151/2007-C and finally approved by the 
CORIT (Consortium for Research in Organ Transplantation) Ethical Committee.  
Experimental xenotransplant model 
In order to obtain a PD-like syndrome due to a progressive degeneration of the 
nigrostriatal dopaminergic system, all monkeys were treated with 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Sigma, Saint Louis, MO, USA) by systemic 
administration, as described.1 Once stable PD lesions were obtained, 24 monkeys 
were unilaterally injected in the left putamen with wild type (n=6) or CTLA4-Ig (n=18) 
transgenic neuronal precursors from pig embryos. All xenotransplanted primates 
were immunosuppressed for the whole duration of the study using a clinically 
applicable regimen: cyclosporine orally from day –2 to achieve 12 hours (hrs) 
through levels of 300 to 500ng/ml (Sandimmun Neoral, Novartis Pharma AG, Basel 
Switzerland), sodium mycophenolate from day +5 to achieve a 12 hrs through levels 
of 3 to 6 mg/ml, (Myfortic, Novartis Pharma AG), prednisone 1 mg/kg orally on days 




(Deltacortene, Hoechst Marion Roussel, Scoppito, Italy). In a group of animals 
(n=13), cyclosporine dosage was gradually decreased starting from day 100 post 
grafting to reach 12 hrs through levels of 50 to 100 ng/ml.1 Xenograft survival and 
function was determined by clinical neurological assessment, analysis of locomotor 
activity (Ethovision software), brain imaging (MRI scan and 18F-DOPA PET studies) 
and histological studies at the end of each experiment.1 
Pathological study 
At the end of each experimental study or on the basis of their clinical condition, 
monkeys were euthanized and perfused transcardially with normal saline followed by 
4% paraformaldehyde (Sigma, Saint Louis, MO, USA). The brains were removed 
and post-fixed for approximately 18 hrs in 4% paraformaldehyde and then 
cryopreserved by immersion in a graded (10-15-20%) sucrose/0.1M phosphate-
buffered saline (pH 7.2) solution. Soon after euthanasia, collection of blood by aorta 
cannulation, cerebrospinal fluid by lumbar puncture, and bone marrow from femur 
were also performed. The primates underwent a complete post-mortem examination 
by a veterinary pathologist (LC) familiar with necropsies of transplanted primates, 
with pictures of every organ and lesion, and samples of all tissues were formalin-
fixed as well as cryopreserved at -80°C. Paraffin-embedded, 3-4 µmthick sections 
were stained with hematoxylin and eosin and observed with a light microscope in a 
blinded manner, by two independent pathologists (LC and SW). 
Additional investigations on neoplastic tissues from 9 of 28 primates included 
immunohistochemistry (IHC) using monoclonal antibodies with the following 
specificities: CD3 (dilution 1:100, clone PC3/188A, DAKO, Milan Italy), CD5 (dilution 
1:50, clone 54/F6 DAKO), CD20 (dilution 1:50, clone L-26, BioGenex, Menarini, 




antibody specific for IE1 protein of rhesus CMV (courtesy of Prof. Peter Barry, 
California Medical Research Center, dilution 1:3000 and antigen retrieval at 95°C for 
60 minute), pancytokeratin (dilution 1:100, clone AE1/AE3 M3515 DAKO), and 
vimentin (dilution 1:100, clone V9 DAKO). Sections (4 µm) were mounted on 
Superfrost Plus microscope slides (Menzel GmbH, Braunschweig, Germany) and 
dried at 37°C for 30 min. All samples were tested with an automated immunostainer 
(Benchmark, Ventana Medical Systems Inc. Tucson, AZ), which included dewaxing 
and rehydration, antigen retrieval, primary antibody incubation, antigen detection 
with ultraView™ Universal Diaminobenzidine (DAB) kit (Ventana Medical Systems) 
and counterstaining with Mayer’s haematoxylin. Finally, slides were manually 
dehydrated through a graded series of alcohols and mounted (Eukitt mounting 
medium, Fort Washington, PA). Primary antibody dilutions were performed using a 
commercial antibody diluent (Ventana Medical Systems). 
For double-labeling IHC, formalin-fixed tissues were sectioned at 5 µm. Slides were 
deparaffinized, rehydrated and then blocked for peroxidase.  Antigen retrieval was 
done in microwave by boiling in citrate buffer (pH 6.0) and cooling for 20 minutes at 
room temperature.  Slides were then blocked sequentially for biotin and DAKO 
protein block.  The slides were incubated with either CD20 (M0755, Dako, 
Carpinteria, CA) or CD3 (Pan T cell Pc #A0452, Dako) for 60’ or 30’ at room 
temperature, respectively, followed by biotinylated secondary for 30’, and the Vector 
ABC Alkaline Phosphatase (Vector Labs, Burlingame, CA). Slides were incubated 
with the liquid permanent red for the cellular marker detection.  Slides were then 
blocked sequentially for biotin, Mouse IgG Blocking Reagent (Vector Labs), 
Universal Block (KPL, Gaithersburg, MD), and DAKO protein block.  Slides were 




(EBNA2) antibody (NCL-EBV-PE2, Novocastra, Leica, Buffalo Grove, IL) followed by 
the biotinylated secondary antibody and Vector ABC peroxidase (Vector Labs). 
EBNA2 detection was performed with chromogen DAB (Dako). Slides were finally 
counterstained with Mayer’s hematoxylin and coverslipped. 
 
Scoring for Ki-67 IHC 
Immunohistochemistry slides for Ki-67 were evaluated by a pathologist and scored 
on a 1+ to 4+ scale based on percent positivity assessed in 5 high power fields (1= 
<25%; 2= 25-50%; 3= %51-75%; 4 = >75%).  
 
Molecular study 
RNA extraction: Total RNA was extracted from PTLD and lymph node specimens 
using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s specifications. The quality of the RNA was checked by gel 
electrophoresis on a 1% agarose gel containing SYBR Safe™ DNA Gel stain 
10,000X (Invitrogen™, Carlsbad, California). RNA concentration was determined 
using a UV-Vis spectrophotometer, NanoDrop® ND-1000 (NanoDrop Technologies, 
Wilmington, USA). 
Amplification of EBNA-1, EBNA-2 and Latent Membrane Protein 1 (LMP-1) cDNAs: a 
total of 300 ng of total RNA was reverse transcribed using a reverse transcriptase 
(Superscript II, Invitrogen) with random hexamers to obtain first-strand cDNA. The 
cDNA was then used as a template for the subsequent PCR reactions. Cycling 
conditions were: initial incubation at 94° C for 2 min followed by 45 cycles at 94°C for 
30 s, annealing temperature for 40 s and 72°C for 40 s. A final extension step at 




annealing temperature was set according to the predicted melting temperature. One 
fifth of each PCR reaction was electrophoresed on a 1.8% agarose gel, stained with 
SYBR Safe™ DNA Gel stain, and visualized under UV light. Primers for amplification 
of EBNA-1 and LMP-1 transcripts were designed according to Cynomolgus LCV 
sequences already stored on GenBank database (www.ncbi.nlm.nih.gov) under 
accession numbers AB037276 and AAD56946, respectively (Supplemental Table 1). 
A first EBNA-2 fragment was amplified using degenerate primers designed on the 
basis of the multiple alignment of publicly available nucleotide sequences of three 
primates LCV transcripts: macacine EBNA-2 (Macaca mulatta Herpesvirus 4, 
AAK95414), papiine EBNA-2 (Papio cynocephalus Herpesvirus 1, AAA79034) and 
human EBNA-2 (Epstein-Barr virus, AAB89222). PCR products were then 
sequenced, and, based on sequenced fragment, a second PCR was carried out 
using a Reverse primer specific for Cynomolgus LCV (Mf_EBNA2_R, see 
Supplemental Table 1) and a Forward primer, designed as reported above, in order 
to increase the length of EBNA-2 sequence.  
PLHV testing: DNA was prepared from porcine peripheral blood mononuclear cells 
(PBMCs) using the Qiagen DNeasy kit (Qiagen, Crawley, UK) according to 
manufacturer’s instructions. Isolated DNA was then screened for the presence of 
PLHV by nested PCR using primer sets previously described.8 All reactions were 
carried out using Core Taq PCR reagents (Qiagen, Crawley, UK). 
Macaque Lymphocryptovirus (macLCV) screening: viral nucleic acid was isolated 
from the macaque sera using the PureLink viral RNA/DNA extraction kit (Life 
Technologies, Paisley, UK). Viral DNA preparations were screened for the presence 
of macLCV DNA by qPCR, using primers designed to correspond to the DPOL gene 




R; 5’- GAATCYTGCACGCAGTACAT-3’ and probe macLCVqPCR-P; 5’-6FAM-
TCGCCTCTTTGCAGAGGGCC-TAMRA-3’) and Taqman Gene Expression Master 
Mix reagents (Life Technologies, Paisley, UK). Amplification was achieved with 40 
cycles of 95°C for 15sec, 53°C 15sec, 60°C 30sec and carried out alongside known 
copy number controls to allow quantification of each sample and to test reaction 
efficiency. All samples were spiked with an Internal Positive Control (Life 
Technologies, Paisley, UK) to test for the presence of inhibitory factors. The assay’s 
limit of detection was 10 virus particles per ml of serum. 
Results 
Pathological study 
Nine of 28 immunosuppressed macaques developed masses compatible with PTLD. 
Seven were recipients of neuronal precursors from CTLA4-Ig transgenic pig 
embryos, 1 from wild-type pig embryos and 1 received only MPTP treatment and 
immunosuppression. Clinical signs that led to euthanasia were related to the 
presence of a nasal mass (n=3), an abdominal mass (n=4), or both (n=2). Signs 
included respiratory noise, deviation of the nasal profile, abdominal pain and 
diarrhea. Clinical signs were detected from 110 to 287 post-operative days (POD) 
(average 172.5). Euthanasia was performed from 117 to 330 POD (average 192.5). 
Macroscopically, nasal masses had different levels of severity, tissue infiltration and 
size. The lesions ranged from diffuse bilateral thickening of nasal mucosa of both 
sides (n=2), to a distinct unilateral mass of 3 mm in diameter (n=1), to a complete 
unilateral to bilateral obliteration of the nasal cavity (n=1), with a wide extension from 
the ethmoid bone to the nostril and a marked deviation of the nasal septum and 
protrusion from the soft palate (n=2). In all subjects with abdominal pain, the bowel 




section, several button-like, 1- to 2-cm-diameter, ulcerated and protruding masses 
were detected, from gastric mucosa (n=1) to small intestine (n=2) or rectum (n=1). In 
addition, a moderate to severe (up to 6 cm in diameter) gastric, pancreatic and 
mesenteric lymph nodal enlargement was observed. In 50% of primates, other 
masses, possibly lymph nodes in origin, were found close to trachea, in the 
mediastinum, in the peritoneum or adjacent to thoracic or abdominal aorta. Only one 
case had a mass in another organ, the adrenal gland. 
Microscopically, the  masses were consistent with large-cell lymphomas composed 
of a diffuse atypical population of round cells, measuring up to 20 µm, with scant to 
moderate eosinophilic cytoplasm, lacking distinct cell boundaries, located within the 
subepithelial connective tissue and occasionally in the epithelium of the nasal cavity, 
intestinal tract as well as many visceral lymph nodes. Occasionally the thoracic and 
visceral masses were severely effaced by the atypical population and a possible 
lymph nodal origin was considered. The cells were organized in broad sheets 
intermingled with a moderate fibrovascular stroma. The nuclei, 10-15 µm diameter, 
were central, round to ovoid, frequently cleaved with finely granular chromatin and 
one prominent nucleolus. There were moderate anisokaryosis and anisocytosis. The 
mitoses were 5 to 20 in 10 high-power fields (Fig. 1 and 2) and scattered apoptotic 
cells were present. In the nasal masses (3 of 3 cases), the atypical population was 
associated with massive necrosis and destruction of the nasal bone. Scattered 
around the periphery of the masses were moderate, multifocal lymphoplasmacytic 
aggregates. As for the intestinal masses, in association with the atypical cells, focally 
extensive areas of necrosis and a peripheral rim of lymphocytes were present. A 
diffuse atypical population with the same features of other locations characterized 




characteristics of all the nodal masses and the nasal and intestinal lesions,  the 
diagnosis in the nine affected primates was of monomorphic PTLD according to the 
patterns described in the WHO classification.21 
IHC revealed a uniform pattern of marker expression in all PTLD tumors examined. 
Neoplastic cells were consistent with B cells, diffusely labeling CD20 (Fig. 3) and 
CD79 and for vimentin intermediate filaments (data not shown for CD79 and 
vimentin). Neoplastic cells were negative for cytokeratins, CMV, CD3 and CD5 
markers; however, CD3+ and CD5+ lymphocytes were scattered at the periphery of 
most tumors, occasionally infiltrating the neoplastic cells (data not shown for CD3 
and CD5). Cellular proliferation, evidenced by expression of Ki-67, was high with 
greater than 50% positivity of the cells (based on at least 5 high power fields) for 
most PTLD tumors. Tumors from multiple sites in the same animal exhibited similar 
proliferation rates. A nasal cavity lymphoma in one primate had a low proliferation 
rate with <25% of cells Ki-67+ (based on at least 5 high power fields). EBNA2 
labeling revealed a diffuse nuclear positivity of the tumors (Fig. 4). 
Double-labeled IHC for CD20 and EBNA2 confirmed LCV infection of CD20-positive 
neoplastic cells of B cell origin (Fig. 5). In one case roughly 90% of EBNA2-positive 
neoplastic cells were CD20-positive B cells, while the remaining 10% were either B 
cells with down-regulated CD20 or were not B cells. In the same case, in another 
section, only 50% of the EBNA2-positive cells were positive for CD20, indicating a 
population of CD20-positive cells that were not LCV-infected. In another case, only 
50% of the EBNA2-positive cells were positive for CD20, while 80% of CD20-positive 
B cells were positive for EBNA2. Double-labeling with CD3 and EBNA2 in this case 
failed to demonstrate that additional EBNA2 positive cells were CD3 lymphocytes 





A preliminary survey on EBNA-1, EBNA-2 and LMP-1 gene expression was carried 
out using end-point RT-PCR on neoplastic cells from five different PTLDs and two 
hyperplastic lymph nodes, confirmed at histology and immunohistochemistry, taken 
from PTLD affected primates. Gene-specific primers were used for both EBNA-1 and 
LMP-1 amplification, one primer pair for EBNA-1 while four different primer 
combinations were employed for LMP-1. EBNA-1 expression was demonstrated in 
all PTLD specimens by the amplification of a region of 453 bp showing a 98.6% 
identity with reference cynomolgus sequences in GenBank, while no expression was 
found in controls. Noticeably, four different RT-PCR assays failed to detect LMP-1 
transcript in any of the specimens (Fig. 7). Degenerate primers designed on the 
multiple alignments of three primate EBNA-2 sequences allowed isolation of the 
cynomolgus LCV EBNA-2 transcript. The sequencing of two overlapping regions led 
to the assembly of a 832 bp sequence (GenBank accession number JQ845949). 
Sequence analysis revealed a 76% identity at the protein level with macacine 
herpesvirus 4 EBNA-2 (AAK95414), but considerably lower homology with human 
and papiine counterparts, showing 49% and 33% identity respectively. The 
cynomolgus LCV EBNA-2 transcript in the present study showed a 99.3% identity at 
nucleotide level with the complete genome of a lymphocryptovirus isolated from 
cynomolgus monkey (NCBI accession number KP676001.1). EBNA-1, EBNA-2 
transcripts were detected in all PTLD specimens, revealing viable virus in neoplastic 
cells, while no expression was observed in hyperplastic lymph nodes (Fig. 7).  
DNA was isolated from PBMCs from the recipients and from the donor pigs. The 
DNA was screened by PCR for the presence of the porcine homologue to EBV, 




donor pool, but all recipients tested negative for PLHV. Pan-herpesvirus screening of 
the macaques and sequencing revealed the presence of the macaque homologue to 
EBV-macaque lymphocryptovirus (macLCV) in all recipients. A quantitative PCR 
assay was developed to detect macLCV and used to retrospectively screen viral 
DNA isolated from the serum of the macaques taken pre-transplant, at euthanasia 
and at intermediate time points post-transplant. The assay showed that the 9 PTLD-
affected macaques had a detectable viremia within 36-278 days (mean 117 ± 30 
days) post-transplant and on average 60 days before the onset of clinical signs (Fig. 
8). There was no detectable viremia in any of the 19 PTLD-unaffected macaques at 
any time point tested.  
 
Discussion 
PTLD are a heterogeneous group of lymphoid proliferations that occur in the setting 
of depressed T-cell function due to immunosuppressive therapy used with solid 
organ transplantation or hematopoietic stem cell transplantation.9 In humans, genetic 
and epigenetic alterations, microenvironment-resident plasmacytoid dendritic cells 
and Treg cells play a critical role, as well as viruses, notably EBV, and contribute to 
the development of PLTDs.21 
The EBV genome exists in humans as an episome in latently infected B cells. 
Activated functional T-cells play a pivotal role in the control of proliferation and 
elimination of EBV-infected cells.15 In immunocompromised subjects, T-cell function 
is impaired, which may lead to uncontrolled proliferation of EBV-transformed cells, 
known as EBV-related PTLD.12 Most Old World NHP are infected with LCV, a 
herpesvirus of the same subgroup as EBV, 22 and several of the LCV products are 




may have considerable potential value in elucidating PTLD pathogenesis and 
diagnosis. In this light, we characterized PTLD occurring in immunosuppressed 
cynomolgus monkeys undergoing neural precursor xenotransplantation to treat a 
pharmacologically induced form of PD.1  
In our case series, PTLD occurred in 32% of animals after a long course of 
immunosuppressive therapy. In particular, we detected clinical signs related to the 
presence of nasal masses that led to difficulties in breathing, to abdominal masses 
that led to abdominal pain or both. Clinical signs occurred on average at 172.5 POD 
and the average time between the occurrence of clinical signs to euthanasia was 20 
days. In the literature of NHP PTLDs, specifically in the context of solid organ 
xenotransplantation, different times of occurrence of this disorder are reported: a 
median of 6.5 and 33.5 POD in Macaca fascicularis models of renal 
xenotransplantation and renal allotransplantation respectively,16 28-103 POD in a 
model of renal transplantation,20 after 6 months of intense immunosuppressive 
therapy in a rhesus macaque model of liver xenotransplantation or Macaca 
fascicularis model of kidney xenotransplantation,23 and 60-177 POD in primates after 
composite facial allografts.3 The present study is the first report of PTLDs occurring 
in the setting of neuronal precursor xenotransplantation in cynomolgus monkeys. All 
our primates were followed for six months after transplantation and 
immunosuppression and are considered long-term survivors. All PTLD cases in our 
study were lymphomas, assuming that the natural development of PTLD progresses 
from a non-neoplastic into a neoplastic lesion. 
All above-mentioned publications from other laboratories have reported extranodal 
masses in xenotransplanted and immunosuppressed primates. In our animals, the 




high density of MALT. In the abdominal cavity of primates with larger alimentary tract 
masses, disseminated enlargement of lymph nodes was observed. In addition, in 
half of the cases, other masses (possibly lymph nodes) were found close to trachea, 
in the mediastinum, or adjacent to thoracic or abdominal aorta. 
Like most human PTLD and AIDS-related diseases, the NHP lymphomas are 
generally of high-grade malignancy.16 The morphology of the masses of all 
xenotransplanted cynomolgus monkeys was similar, revealing a centroblastic diffuse 
B-cell lymphoma with high proliferation rate assessed with Ki67 immunolabeling. 
According to the most recent WHO classification of PTLD21 these lymphomas are 
classified as monomorphic lymphomas.  
In order to assess whether PTLDs are associated with LCV two different techniques 
were used, IHC and PCR. The IHC findings revealed that the neoplastic cells were 
diffusely positive for the EBNA2 viral protein. Double-labeling for CD20 and EBNA2 
confirmed that LCV infection of CD20-positive neoplastic B cells.   
When EBV infects a B lymphocyte, the virus expresses genes encoding proteins 
involved in viral DNA replication and viral particle synthesis. These include EBV 
nuclear antigens, EBNAs, and three latent membrane proteins (LMPs) associated 
with transforming activity.7 In particular, EBNA-1 supports the EBV genome as a 
circular episome and is an important protein for immortalization and tumorigenesis of 
infected cells, and EBNA-2 stimulates B-cell proliferation through up-regulation of 
LMP1 and prevents reactivation from latency by upregulating the expression of 
LMP2. In addition, EBV proteins have properties that help avoid host immune 
responses. During latent infection, EBV-infected B cells are protected from apoptosis 




other proteins that inhibit apoptosis and activates the NF-B signaling pathway to 
stimulate cell growth. In humans, EBV-associated malignant diseases can be divided 
into three patterns of latency, depending on the viral genes expressed. In type III 
latency, all latency genes are expressed and development of PTLD occurs.6 In our 
study, PCR revealed diffuse expression of EBNA-1 and EBNA-2 in neoplastic 
tissues, in comparison to reactive lymph nodes of the same animals. In contrast to 
what is observed in humans, we detected only the expression of EBNA-1 and EBNA-
2 and not LMP-1 revealing a possible new pattern of viral protein expression during 
the development of PTLD in nonhuman primates. 
In order to establish whether variation of viral DNA could be an early diagnostic tool 
for PTLD progression in primates, we designed a quantitative PCR that was used on 
sera of three distinct phases of the experimental life of our primates: pre-transplant, 
post-transplant (an intermediate time between transplantation and euthanasia) and 
euthanasia. EBV monitoring in humans suggests that high EBV loads are only 
predictive of PTLD if associated with low cytotoxic T cell responses.  Instead, in the 
present study, the data suggest that macLCV monitoring may be valuable in the 
early detection of PTLD in non-human primate xenotransplantation trials, allowing 
pre-emptive treatment such as a reduction of immunosuppression therapy. In 
addition, there was no evidence of PLHV zoonotic transmission through 
xenoneuronal grafts in this study. 
In conclusion, even if a systemic immunosuppression was needed to sustain the life 
of a neuronal cell graft in this Parkinson’s disease xenotransplantation model, PTLD 
occurred in a third of the immunosuppressed Macaca fascicularis recipients of the 
graft. incomparable to human transplant patients, PTLD is related to the presence of 




neoplastic cells. Interestingly, serologic screening of the viral DNA load in the 
recipients during the post transplantation phase ruled out a possible donor-derived 
infection. The clinical application of viral DNA monitoring could be of help in 
identifying a possible early onset of the disease and a consequent adjustment of the 
immunosuppressive regimen could be applied. 
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FIGURE 1-6 Monomorphic PLTD, nasal cavity, Macaca fascicularis: 1 HE. 
Diffuse and dense cellular population. 2 Same cellular population as 1, HE. The 
cells, 20 µn are round with scant eosinophilic cytoplasm with no distinct cell 
boundaries. The nuclei, 10-15 µn are central, round to ovoid, with finely granular 
chromatin and one prominent nucleolus. Occasional mitoses are present (arrows). 3 
IHC for CD20, shows a diffuse brown cytoplasmic positivity for neoplastic cells. 4 
IHC for EBNA2, shows a diffuse brown nuclear positivity for neoplastic cells. 5 
Double-labeled IHC for CD20 (cytoplasmic, brown) and EBNA2 (nuclear, red), shows 
a diffuse double, cytoplasmic and nuclear positivity confirmed LCV infection of CD20 
positive neoplastic cells. 6 Double-labeled IHC for CD3 (membranous, brown) and 
EBNA2 (nuclear, red), shows scattered CD3 positive cells among EBNA2 nuclear-
positive cells.  
FIGURE 7: RT-PCR analysis of cynomolgus EBNA-1, EBNA2 and LMP-1 mRNA 
expression. Samples P1, P2, P3, P4 and P5 are Post Transplant Lymphoproliferative 
Disorder positive (PTLD+) primates; samples L4 and L5 are hyperplastic lymph 
nodes from P4 and P5 PTLD+ primates. M, molecular marker; C No Template 
Control. EBNA-1, EBNA-2 transcripts are detected in all PTLD specimens, while no 
expression is observed in hyperplastic lymph nodes. 
FIGURE 8: Lymphocryptovirus (LCV) viremia levels in Post-Transplant 
Lymphoproliferative Disorder (PTLD) affected animals. No viremia was detected in 
PTLD-negative animals. 
